William Blair reiterates BridgeBio stock rating after Pfizer settlement By Investing.com

William Blair reiterated an Outperform rating on BridgeBio Pharma and raised its fair value estimate to $93.49, citing settlement-driven clarity around tafamidis patent expiry and a stronger path to growth. BridgeBio’s revenue rose 126% over the last twelve months to $502 million, and management is expected to approach cash flow positivity and GAAP profitability in late 2027. The stock is trading at $71.26, with additional analyst support from Mizuho ($106), Piper Sandler ($111), and H.C. Wainwright ($100).

Analysis

The main market implication is not just de-risking of BridgeBio’s lead asset, but a longer-duration competitive moat: extending the effective patent window for tafamidis reduces the probability of a near-term payer cascade into broad generic pricing, which preserves the economics of the entire TTR category. That matters because the category is likely to stay functionally single-drug for longer than many investors assumed, and in orphan/cardiometabolic niches, one entrenched brand can keep formulary access and physician habit even after share erosion begins.

For BBIO, the bigger second-order effect is capital allocation optionality. If management can layer three launches on top of Attruby before mid-2031 generic risk becomes real, the stock may rerate from a one-asset commercial story to a self-funding platform, which usually compresses the discount rate sharply in biotech. The market is likely underappreciating how much of the current valuation gap closes once GAAP profitability becomes visible; that inflection can matter more than peak sales, because it broadens the shareholder base from growth-only funds to quality-biotech and crossover capital.

The key risk is that this is still a litigation-driven setup, not a clean operating de-risk. A bad readout in the TTR-CM background subgroup from the Ionis/AZ program would not help BBIO directly, but it could reset payer expectations for the entire class and narrow the shelf life of premium pricing faster than modelers expect. On the flip side, if coverage restrictions remain stringent, the market may be overestimating the pace at which generic tafamidis can pressure net pricing; the real erosion could be delayed and more back-end loaded than the current narrative implies.

Key Decisions for Investors

• Maintain/expand long BBIO into the April 30 print with a 3-6 month horizon; best risk/reward is if management confirms launch cadence and cash-flow trajectory, while downside is capped if litigation optimism is already partially in the price.
• Consider a BBIO / PFE pair trade: long BBIO against short PFE on a 6-12 month view, targeting relative multiple expansion in BBIO versus limited incremental upside for PFE after patent-extension news.
• Buy BBIO upside via call spreads rather than outright shares into earnings; use a 3-6 month tenor to express rerating potential while limiting drawdown if the market sells the event.
• For more risk-controlled exposure, pair long BBIO with short AZN or IONS into the 2H26 catalyst window if you believe payer restrictions keep the TTR market more protected than consensus expects; the short leg only works if the subgroup readout disappoints or fails to broaden usage.
• Trim into strength if BBIO approaches the upper end of sell-side targets before evidence of operating leverage; the stock can rerate fast, but the catalyst path remains binary and litigation-sensitive.